This FXR agonist was used as a reference drug for NASH treatment due to its clinical potency in decreasing steatosis, hepatocellular ballooning, lobular inflammation, and fibrosis [29,33] (Figure 1A). This evidence concerns the gene NR1H4 and steatosis.